好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Genetic Testing in Idiopathic Optic Neuropathy: Diagnostic Yield and Differences in Clinical Presentation
Neuro-ophthalmology/Neuro-otology
P10 - Poster Session 10 (8:00 AM-9:00 AM)
17-009

To determine the diagnostic yield of genetic testing in idiopathic optic neuropathy and to compare clinical characteristics of patients with a confirmed genetic etiology of their optic neuropathy to those with negative testing.

Chronic optic neuropathy classically presents with visual acuity loss, dyschromatopsia, and optic atrophy. Identifying an underlying cause is essential for management; yet many cases remain idiopathic even after comprehensive neuro-ophthalmologic evaluation. Advances in genetic testing now allow for detection of hereditary etiologies that may mimic acquired optic neuropathies.

A cross-sectional study was conducted for a convenience sample of patients with chronic optic neuropathies who underwent genetic testing following nondiagnostic neuro-ophthalmologic evaluation. Clinical characteristics, including color vision (Ishihara plates), high-contrast visual acuity, low-contrast letter acuity, visual field mean deviation (VFMD), and peripapillary retinal nerve fiber layer (pRNFL) thickness by optical coherence tomography (OCT), were compared between eyes of patients with vs. without a confirmed genetic diagnosis.  Generalized estimating equation models (GEE) were used to examine whether having a confirmed genetic diagnosis was associated with worse scores/measurements.  Only clinically affected eyes were included, with most patients contributing data for both eyes.  

There were 26 patients; all had received genetic testing.  The proportion who had a genetic diagnosis was 11/26 (42% [95% CI, 23%, 61%]). The most frequent pathogenic variants involved WFS1 and MT-ND4. At initial evaluation, eyes in the genetic group demonstrated less visual field loss (average VFMD −2.2 vs. −11.8 dB; difference +9.3 dB (95% CI 2.8, 15.9; p=0.005).  No significant differences were observed for other tests.

Our results demonstrate that hereditary optic neuropathies can present with subtle or variable phenotypes, supporting the inclusion of genetic testing even in mildly affected idiopathic cases.  The visual field was a key test that separated our two groups. Genetic testing may have high yield in patients with chronic idiopathic optic neuropathy. 

Authors/Disclosures
Nagashreyaa Nagajothi
PRESENTER
Miss Nagajothi has nothing to disclose.
Samuel Lee, MD Dr. Lee has nothing to disclose.
Caroline R. Mura, MS Ms. Mura has nothing to disclose.
Connolly Steigerwald, CGC Ms. Steigerwald has received personal compensation for serving as an employee of Ambry Genetics. Ms. Steigerwald has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Vigil Neuroscience.
Rachel Kenney Rachel Kenney has received personal compensation for serving as an employee of Optum. Rachel Kenney has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Minton 好色先生 LLC.
Steven Galetta, MD, FAAN (NYU Langone Medical Center) Dr. Galetta has nothing to disclose.
Laura J. Balcer, MD, MSCE, FAAN (NYU Grossman School of Medicine) An immediate family member of Dr. Balcer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Children's Hospital of Philadelphia.
Nicolas J. Abreu, MD (NYU Langone) Dr. Abreu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Abreu has received research support from Adult Polyglucosan Body Disease Research Foundation. The institution of Dr. Abreu has received research support from Sanofi Genzyme. The institution of Dr. Abreu has received research support from Takeda. The institution of Dr. Abreu has received research support from Sangamo. The institution of Dr. Abreu has received research support from BDSRA Foundation.
Scott Grossman, MD (New York University, Langone Health) Dr. Grossman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acuta Pharmaceuticals.